Production (Stage)
Fresh Tracks Therapeutics, Inc.
FRTX
OTC PK
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 15.31% | 101.24% | -44.04% | 1,332.15% | 1,618.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.31% | 101.24% | -44.04% | 1,332.15% | 1,618.56% |
| Cost of Revenue | -77.34% | -60.31% | -58.95% | -64.65% | -50.26% |
| Gross Profit | 167.94% | 144.76% | 63.13% | 88.79% | 74.49% |
| SG&A Expenses | -22.52% | -0.77% | -19.29% | 3.29% | 16.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.55% | -31.46% | -43.22% | -43.28% | -29.94% |
| Operating Income | 70.47% | 59.99% | 43.09% | 59.49% | 46.49% |
| Income Before Tax | 73.02% | 60.33% | 42.75% | 59.96% | 46.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.02% | 60.33% | 42.75% | 59.96% | 46.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.08% | 59.46% | 42.75% | 59.96% | 46.54% |
| EBIT | 70.47% | 59.99% | 43.09% | 59.49% | 46.49% |
| EBITDA | 70.61% | 60.11% | 43.16% | 59.54% | 46.54% |
| EPS Basic | 81.34% | 68.46% | 62.67% | 74.92% | 67.98% |
| Normalized Basic EPS | 81.07% | 68.29% | 62.71% | 75.29% | 68.39% |
| EPS Diluted | 81.34% | 68.46% | 62.67% | 74.93% | 67.99% |
| Normalized Diluted EPS | 81.07% | 68.29% | 62.71% | 75.29% | 68.39% |
| Average Basic Shares Outstanding | 91.98% | 75.11% | 62.95% | 46.14% | 57.16% |
| Average Diluted Shares Outstanding | 91.98% | 75.11% | 62.95% | 46.14% | 57.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |